Literature DB >> 25969952

MDM2 binds and inhibits vitamin D receptor.

Kristina Heyne1, Tessa-Carina Heil, Birgit Bette, Jörg Reichrath, Klaus Roemer.   

Abstract

The E3 ubiquitin ligase and transcriptional repressor MDM2 is a potent inhibitor of the p53 family of transcription factors and tumor suppressors. Herein, we report that vitamin D receptor (VDR), another transcriptional regulator and probably, tumor suppressor, is also bound and inhibited by MDM2. This interaction was not affected by vitamin D ligand. VDR was ubiquitylated in the cell and its steady-state level was controlled by the proteasome. Strikingly, overproduced MDM2 reduced the level of VDR whereas knockdown of endogenous MDM2 increased the level of VDR. In addition to ubiquitin-marking proteins for degradation, MDM2, once recruited to promoters by DNA-binding interaction partners, can inhibit the transactivation of genes. Transient transfections with a VDR-responsive luciferase reporter revealed that low levels of MDM2 potently suppress VDR-mediated transactivation. Conversely, knockdown of MDM2 resulted in a significant increase of transcript from the CYP24A1 and p21 genes, noted cellular targets of transactivation by liganded VDR. Our findings suggest that MDM2 negatively regulates VDR in some analogy to p53.

Entities:  

Keywords:  MDM2; transcription; tumor suppression; vitamin D; vitamin D receptor

Mesh:

Substances:

Year:  2015        PMID: 25969952      PMCID: PMC4613177          DOI: 10.1080/15384101.2015.1044176

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  35 in total

Review 1.  Posttranslational modification of MDM2.

Authors:  David W Meek; Uwe Knippschild
Journal:  Mol Cancer Res       Date:  2003-12       Impact factor: 5.852

2.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

Review 3.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

4.  Vitamin D directly regulates Mdm2 gene expression in osteoblasts.

Authors:  Hankui Chen; Grant Reed; Janete Guardia; Sandeep Lakhan; Oliver Couture; Emily Hays; Nalini Chandar
Journal:  Biochem Biophys Res Commun       Date:  2012-11-10       Impact factor: 3.575

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

6.  The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.

Authors:  M S Sheikh; Z M Shao; A Hussain; J A Fontana
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

7.  The human MDM-2 oncogene is overexpressed in leukemias.

Authors:  C E Bueso-Ramos; Y Yang; E deLeon; P McCown; S A Stass; M Albitar
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

Review 8.  Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention.

Authors:  Mark R Haussler; Carol A Haussler; Leonid Bartik; G Kerr Whitfield; Jui-Cheng Hsieh; Stephanie Slater; Peter W Jurutka
Journal:  Nutr Rev       Date:  2008-10       Impact factor: 7.110

9.  Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.

Authors:  Chihiro Ohtsubo; Daisuke Shiokawa; Masami Kodama; Christian Gaiddon; Hitoshi Nakagama; Aart G Jochemsen; Yoichi Taya; Koji Okamoto
Journal:  Cancer Sci       Date:  2009-04-27       Impact factor: 6.716

Review 10.  MDM2, an introduction.

Authors:  Tomoo Iwakuma; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2003-12       Impact factor: 5.852

View more
  2 in total

Review 1.  Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook.

Authors:  Jörg Reichrath; Christos C Zouboulis; Thomas Vogt; Michael F Holick
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 2.  The vitamin D receptor: a tumor suppressor in skin.

Authors:  Daniel D Bikle
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.